CERBA-RESEARCH
Cerba Research , a leading global clinical trial laboratory services organization owned by Cerba HealthCare, announced today that they have joined forces with ACT Genomics under a joint venture model to create a purpose-built lab facility in Taiwan covering the Asia Pacific region.
This expansion of the precision medicine offering includes central labs, flow cytometry, histopathology, and translational science laboratory services. Deep scientific expertise from both sides of this strategic alliance will support new growth areas for biotech and pharma clients globally and drive better patient outcomes across all phases of clinical trials.
The expansion includes investments in a new facility in Taipei (Taiwan) and state-of-the-art technologies to strengthen capabilities and services offered to our clients on a truly global scale:
- Cutting-edge flow cytometry technologies
- Exploratory as well as In Vitro Diagnostic histopathology services
- Peripheral blood mononuclear cell (PBMC) isolations from blood and soft tissues
Progress on construction, technology transfers, and expansion of the scientific team will enable the CerbACT Asia Laboratory to be fully operational in September 2021.
Mario Papillon, CEO of Cerba Research comments: “This milestone with ACT Genomics validates our innovative history as a company. We will support our customers with the latest instrumentation and automation — backed by experienced scientists whose ambition and agility to meet patients’ needs drive our continuous evolution as a company.”
“We are excited to create a partnership with Cerba Research. Together, we offer a broader range of top-notch technologies and services in Asia. The formation of CerbACT Asia echoes our firm dedication in the well-being of cancer patients, keen commitment to society, and unequivocal embrace of precision medicine,” says Hua Chien Chen, CEO, ACT Genomics.
About Cerba Research
Cerba Research is a leading healthcare company with end-to-end drug development and diagnostic solutions to optimize R&D drug productivity and commercialization. Providing early phase research, clinical development through central laboratory and diagnostic services, assay and biomarker development and validation. Working with government agencies, non-government organizations as well as pharma and biotech organizations to change the shape of clinical development. Cerba Research is part of Cerba HealthCare, a leading player in medical diagnosis.
About ACT Genomics
ACT Genomics is an innovation-driven cancer solution provider in Asia with offices in Taipei, Hong Kong, Singapore, Tokyo, and Wales (U.K.). With our Next-Generation Sequencing (NGS) technology, CAP-accredited laboratories, experienced bioinformatics team, and proprietary AI algorithms, we provide optimal cancer treatment planning, immunotherapy evaluation, cancer relapse & drug resistance monitoring, as well as cancer risk assessment services to medical professionals. Together, we “Turn Genomics into Action.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20210824005259/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celebrate Excellence: 2026 SPIE Prism Awards Open for Outstanding Photonics Products9.7.2025 18:07:00 CEST | Press release
The winners will be announced 21 January at SPIE Photonics West Applications are now open for the 2026 SPIE Prism Awards. The awards, presented by SPIE, the international society for optics and photonics, recognize the most innovative products on the market, across the growing range of optics and photonics applications. The annual industry event will celebrate its 18th anniversary on 21 January, during a gala evening at SPIE Photonics West. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709679785/en/ SPIE is now welcoming submissions for its 2026 Prism Awards. In 2026, award category areas will include biophotonics instruments, cameras and imaging systems, lasers, optical materials and components, quantum tech, sensors, test and measurement, and XR tech. And now in its third year, SPIE will showcase the SPIE Catalyst Award, recognizing for-profit companies with programs that expand workplace access and opportunity, streng
SK Capital Has Entered Into Exclusive Negotiations to Acquire LISI Group’s Medical Division9.7.2025 17:45:00 CEST | Press release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors, today announced that its affiliate has entered into exclusive negotiations with LISI Group (Euronext: FII) to acquire LISI Group’s Medical division (“Lisi Medical” or the “Company”). The transaction remains subject to the approval of the competent antitrust authorities, foreign direct investment control authorities and to the information and consultation processes of the relevant employee representative bodies in accordance with applicable laws. As such, the transaction is expected to close in the second half of 2025. Lisi Medical is a leading MedTech CDMO focused on the production of high-precision metal components and assemblies serving global medical device original equipment manufacturers (“OEMs”). The Company’s products include instruments utilized in minimally invasive and robotic-assisted surgery as well as orthopedic implan
LambdaTest Enables Playwright Testing on iOS Real Devices to Enhance Mobile Test Accuracy9.7.2025 17:00:00 CEST | Press release
New capability enables QA teams to automate Playwright scripts on real iPhones and iPads for unmatched mobile testing precision LambdaTest, a GenAI-powered quality engineering platform, has announced support for Playwright testing on real iOS devices, enabling mobile web teams to run automated tests on actual iPhones and iPads using Safari. This update helps QA and engineering teams validate user experiences with far greater accuracy than simulators or emulators can offer. Testing mobile web apps on virtual environments often leads to discrepancies in real-world behavior such as missed touch interactions, inconsistent browser rendering, and undetected performance bottlenecks. LambdaTest now eliminates that uncertainty by allowing developers to execute Playwright tests on physical iOS devices. While Playwright itself does not natively support real iOS hardware, LambdaTest’s integration bridges that gap, providing seamless access to Apple’s Safari browser on real devices. Users can integ
Rimini Street to Report Second Quarter 2025 Financial Results on July 31, 20259.7.2025 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 31, 2025. The company will host a conference call and webcast on that date to discuss the second quarter 2025 results and the 2025 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709364967/en/ Rimini Street to Report Second Quarter 2025 Financial Results on July 31, 2025 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini St
Obsidian Security Expands Go-to-Market Leadership Team to Scale SaaS Protection in the Age of AI9.7.2025 15:00:00 CEST | Press release
Leading SaaS Security Platform Strengthens Executive Bench with Five Strategic Hires as Company Scales Ahead of Growth Funding Obsidian Security, the leading SaaS security platform trusted by global enterprises including Snowflake, T-Mobile, and Pure Storage, today announced the expansion of its go-to-market leadership team with five strategic appointments. These hires position Obsidian to scale its operations as the company addresses the rapidly evolving security challenges posed by agentic AI and accelerates toward long-term growth and IPO readiness. The company has appointed Alison Tierney as VP of Go-to-Market (GTM) Strategy, Corey Elinburg as Field Chief Technology Officer, Brian McHenry as Vice President (VP) of Worldwide Solutions Engineering, Tina Lei as VP of Revenue Marketing, and Tyler Mihevc to lead Mid-Market expansion. These appointments build upon Obsidian's recent hire of Chief Product Officer (CPO) Khanh Tran, former VP of Product Management at CrowdStrike, as the comp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom